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Theimmune response to xenogeneic organ transplants(grafts from other species)
is more potent than to allogeneic tissues (1). In many cases, this extra strength results
from the existence of preformed "natural" antibodies that mediatehyperacute rejec-
tion . However, even in situations such as skin grafting, where antibody-mediated
mechanisms are not thought to play a role, cell-mediated xenograft immunity is
stronger than that to allografts (1, 2) . To examine the cell-mediated response to
xenogeneic compared with allogeneic antigens, we used anti-T cell antibodies in vivo
in mice in an effort to prolong xenogeneic compared with allogeneic skin graft sur-
vival . The results of these studies show that in vivo treatment of mice with an anti-
CD4 antibody prolonged survival ofskin xenografts from rabbitsor monkeys without
prolonging survival ofwhole MHC-mismatched allografts from other mice.
These results represent the firstachievement of better xenograft than allograft sur-
vival for such disparate species combinations . On the one hand, that achievement
creates something of aparadox : why is cell-mediated xenogeneic immunity so powerful
when it apparently lacks a CD4-independent pathway available in allogeneic responses?
On the other hand, the prolongation of xenograft survival by anti-CD4 antibody
is similar to the prolongation ofminor antigen-disparate allograft survival by the
same reagent . This similarity may provide aclue to understanding themechanisms
ofxenograft rejection and mayalso suggestapossible approach for clinical xenogeneic
transplantation .
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Materials and Methods
BriefDefinitive Report
Animals .
￿
C57BL/6J and BALB/c mice were obtained from The Jackson Laboratory (Bar
Harbor, ME) . Cynomolgus monkeys and New Zealand White rabbits were obtained from
Charles River Breeding Laboratories (Wilmington, MA). Skin from the monkeys and rabbits
was procured after animals had been killed in the course of other experiments .
In Vivo Procedures .
￿
Thymectomies were performed on 6-8-wk-old mice using the suction
pipet technique . Chloral hydrate anesthesia was used, supplemented by ether . Mice were rested
at least 1 wk before further manipulation . Skin grafts were performed with the same anesthesia
by preparing a bed on one or both lateral thoracic walls . Grafts were held in place by plaster
bandages for 1 wk . Split thickness grafts (0.3-0.45 mm) were harvested from cynomolgus
monkeys using a Padget dermatome, stored overnight at 4°C in 20% FCS/RPMI with 10%
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gentamicin, and applied in 1.0-1.5-cm2 rectangles to the lateral thorax. Rabbit skin was
bluntly dissected from the cartilage of the concave aspect of the ear, stored overnight at 4°C
in 20o7o FCS/RPMI with 10% gentamicin, and applied in 1.0-1.5-cm2 rectangles. BALB/c
trunk skin was harvested, cleaned of subcutaneous fat and vessels, and stored overnight as
above. Complete epithelialdestruction, "tanning" (loss ofpliability with evolution of leathery
appearance), and shrinkage to <10To oforiginal surface area were used as independent end-
points of rejection. Allografts and some xenografts showed confluent erythema and edema
followed promptly by epithelial loss (typical allogeneic rejection). Some rejecting xenografts,
particularly in the GK1.5-treated group, exhibited a petechial or hemorrhagic pattern fol-
lowed by tanning. Other xenografts, particularly those survivingfor>20 d, underwent gradual
shrinkage, with recurrent episodes of focal erythema preceding subtotal epithelial loss.
mAbs.
￿
Mice were treated intraperitoneally on the days indicated with 0.1 ml of ascites
of GK1.5 anti-CD4 antibody (3), 2-43 anti-CD8 antibody (4), or both together as we have
described before (5).
Cyclosporine.
￿
Oral C&A solution (Sandimmune; Sandoz, Basel, Switzerland) was used for
in vivo treatment. CsA was diluted in olive oil to 5 mg/ml and then administered to mice
by subcutaneous injection starting on the day before grafting.
Results
C57BL/6J (B6) mice were thymectomized and treated with anti-CD4, anti-CD8,
or both antibodies together. Previous studies in our laboratory and by others have
shown that treatment with these antibodies can deplete their respective T cell sub-
populations and achieve in vivo immunosuppression (5-9). The performance of a
thymectomy in the recipient prolongs this immunosuppression for many weeks (5).
Mice treated in this manner received monkey skin grafts. The results shown in Fig.
1 reveal that xenogeneic skin grafts were rapidly rejected in untreated recipients.
Anti-CD8 antibody also failed to prolong graft survival . On the other hand, most
xenogeneic skin grafts were maintained for 30 d on mice treated with both anti-CD8
and anti-CD4 antibodies together. Anti-CD4 antibody alone also caused significant
prolongation ofgraft survival. Over the course of many experiments some xenogeneic
skin grafts have survived as long as 1 mo after anti-CD4 treatment.
These results were in contrast to those previously obtained and reported by us
for whole MHC-disparate allogeneic skin grafts since anti-CD4 antibody alone had
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FIGURE 1.
￿
Survival of monkey skin grafts on B6 mice treated with anti-T cell mAbs. Data are
combined from two experiments with identical protocols. Each group had between 9 and 13 mice
that were treated with antibody on days -3, -1, +4, +8, and +18 with respect to grafting.not been very successful in prolonging survival of these grafts (5). In our experi-
ments, CD4+ lymphocyte depletion has only prolonged survival of class II-disparate
skin grafts and those differing only in their minor histocompatibility antigens (6-8,
10, 11) . Others, however, haveshownsome prolongation ofwhole MHC-mismatched
allografts by anti-CD4 antibody treatment (7-9) . Therefore, to compare the sur-
vival of allografts and xenografts directly, thymectomiaed mice were treated with
anti-CD4 antibodyandthen given grafts from both allogeneicandxenogeneic donors,
oneon each thoracic wall . Typical graft survival in such an experiment (using rabbit
skin) is shown in Fig. 2. Most animals treated with the anti-CD4 antibody main-
tained intact xenografts aftertheyhad rejected the allogeneic skin . Fig. 3 shows pho-
tographs of typical graft appearances in untreated and anti-C134-treated mice . The
viability of the xenogeneic skin grafts was demonstrated by their uptake of fluores-
cein revealed under the Woods lamp and by pathologic examination. The results
were further confirmed in multiple experiments using rabbit or monkey skin and
using BALB/c recipients in addition to B6 mice .
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FIGURE 2 .
￿
Survival of xenogeneic rabbit skin and allogeneic BALB/c skin on B6 mice. Groups
had between four and five mice. Treated animals received 0.1 ml of ascites intraperitoneally on
days -2 and -1 before grafting.
FIGURE 3 .
￿
Typical appearance of skin grafts in the experiment shown in Fig . 2 . (A) An un-
treated control mouseon day 14 with rejected BALB/c skin on the left and rejected rabbit skin
on the right . (B)A mouse treated with anti-CD4 antibody with rejected BALB/c skin on the
left on day 14 but intact rabbit skin on the right .994
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FIGURE 4.
￿
Survival of monkey skin on B6 mice treated with anti-CD4 antibody plus cyclospo-
rine. Three to five mice were in each group. Mice were thymectomized, treated with antibody,
and given monkey skin grafts as in Fig. 1. CsA oral solution was administered subcutaneously
starting thedaybefore grafting. Thenumber afterCsAin parentheses indicates thedose in mg/kg/d
based on 25 g/mouse administered to each group.
Anti-CD4 treatment generally prolonged xenograft survival in our experiments
by 2-3 wk. In an effort to achieve even longer graft survival, we tested other forms
ofimmunosuppression alone andin combination with the anti-CD4 antibody. CsA
alone had little effect on xenogeneic skin graft survival even when used at 50 mg/kg/d,
a dose that we have found prolongs graftsurvival in many allogeneic combinations.
ExperimentscombiningCsAwith anti-CD4 treatment, however, revealed amarked
synergy between them. The results in Fig. 4 show that even 20 mg/kg/d ofCsA was
synergistic with anti-CD4 treatment and that 40 mg/kg/d plus antibody achieved
>30-d graft survival in all mice tested. This synergy is not specific to xenografts since
we have observed it for allografts as well. These results, however, suggest that CsA
might augment theimmunosuppression ofanti-CD4 antibodies forxenogeneic trans-
plantation.
Discussion
Only once before have experimentsrevealed more prolongedsurvival ofxenogeneic
than allogeneic skin on individual recipients. Those studies involved aclosely related
rat-mouse combination undertreatmentwith antilymphocyte serum(12). The present
report, therefore, describes a striking outcome in such disparate species as the mouse
and monkey.
The basic observation in these studies is that CD8+ T cells alone are less able
to mediate xenograft rejection than MHC-disparate allograft rejection. In the case
of MHC-mismatched allografts, that CD4-independent pathway has been attrib-
uted to the function of IL-2-producing CD8+ lymphocytes, whichcan provide their
own"help" in generating cytotoxiceffector cells(13). Ifso, then in thecase ofxenografts,
such IL-2 producing CD8+ cells do not appear to function. In vitro investigation
of helper-independent CD8+ cells has found that they do not function in response
to class II MHC antigens or in response to selfclass I MHC antigens when modified
as if presenting the peptides of nominal antigens (14). Thus, the question emerges
whether the absence of CD4-independent xenograft rejection indicates that xeno-
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MHC antigens, unlike allo-MHC antigens, must undergo antigen processing and
presentation (perhapsentirely in associationwith class II antigens) in order to elicit
animmune response. Minorhistocompatibility antigens, like nominalantigens, also
requireantigenprocessingand presentationonMHC molecules(15). As forxenografts,
anti-CD4 antibody treatment has also been found to prolong the survival ofminor
antigen-disparate, MHC-matched allografts (6-8). Thus, again there is cause to
consider whether xeno-MHC antigens may require antigen processing.
The notion thatxeno-MHC antigens might not be recognized in thesamemanner
as allo-MHC antigens has been discussed before. Some have speculated that the
T cell repertoire, biased toward recognition ofself-like MHC antigens, might find
xenogeneicMHC antigens too dissimilar fromselfin theircritical epitopes (reviewed
in reference 1). Alternatively, recognition ofxenogeneic MHC molecules on APCs
ofanotherspeciesmightinvolve accessorymoleculesorarequirement forlymphokines
that cannot function across species barriers (16). In either case, the immune response
to the xenogeneic MHC antigens would require the processing and presentation
ofpeptides ofthese antigens on MHC molecules on APCs ofthe recipient species.
The hypothesis that xenogeneic MHC antigens function as minor histocompati-
bility antigens would explainthe absence ofaCD4-independent pathway inxenograft
rejection. Inaddition, the hypothesis is notincompatible with the observed strength
of cell-mediated xenograft destruction. Minor histocompatibility antigens do not
necessarilycauseweakgraft rejectionespecially when multiple minordisparities exist
together (17). The many disparities ofxenogeneic grafting would elicit an extreme
expression of the cell-mediated mechanisms of minor antigen rejection.
Whilecell-mediated xenograftrejectionis a powerful event, theobservations reported
here provide evidence that well-selected immunosuppression can overcome this re-
sponse even while leaving other elements of the immune system intact. Although
successful performance of some forms ofclinical xenogeneic transplantation must
await improvements in ourability to controlpreformed antibody, successful achieve-
ment ofothers (such as liver or pancreatic islet transplantation, which may not be
as susceptible to antibody-mediated rejection) might be accomplished in the near
future using anti-CD4 plus CsA treatment.
Summary
B6 mice were treated in vivo with anti-CD4, anti-CD8, or both anti-T cell anti-
bodies together in an effort to prolong xenogeneic compared with allogeneic skin
graft survival. Mice treated with anti-CD4 antibody showed prolonged survival of
xenogeneic monkey or rabbit skin even after they had rejected whole MHC-dis-
parate allogeneic mouse skin. Furthermore, the addition ofcyclosporine was syner-
gistic withthe anti-CD4 antibody in prolonginggraft survival. Theseresultssuggest
that the cell-mediated response to xenogeneic antigens is especially dependent on
CD4+ lymphocytes, a feature shared by the response to allogeneic minor histocom-
patibility antigens. In addition, the results suggest a possible approach to clinical
immunosuppression for some forms of xenogeneic transplantation.
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